{
    "pmid": "41448007",
    "title": "Timing of intra-articular injection of adipose-derived mesenchymal stem cells affects cartilage integrity and IL-18 expression in spontaneous osteoarthritis: A preclinical study.",
    "abstract": "Osteoarthritis (OA) is a progressive joint disease primarily characterized by cartilage degradation. A phase I/II clinical trial demonstrated the therapeutic efficacy of a human adipose-derived mesenchymal stem cell (ADMSC) product in patients with knee OA. However, it remains unclear whether its efficacy varies with disease stage or whether a single intra-articular dose offers sustained protection. In this study, we used STR/ort mice-a spontaneous OA model-to evaluate the effects of a single ADMSC injection administered during either early or advancing-stage OA. An additional group received early-stage treatment and was analyzed at a later time point to assess durability. Cartilage integrity, chondrocyte phenotypes, serum cytokines, and subchondral bone structure were examined at three defined time points. Early ADMSC injection significantly reduced matrix-nonproducing chondrocytes, lowered Osteoarthritis Research Society International (OARSI) scores, suppressed aggrecan fragment and matrix metallopeptidase 13 (MMP-13) expression, and increased SRY-box transcription factor 9 (SOX9) levels. In situ RNA hybridization showed that ADMSC xenografts transiently adhered to the cartilage surface and remained detectable post-injection. Micro-computed tomography (micro-CT) demonstrated restored trabecular architecture, while cytokine profiling revealed reduced interleukin-18 (IL-18) levels in both serum and cartilage. These therapeutic effects persisted for up to six weeks but diminished by ten weeks post-injection. In contrast, ADMSC treatment during advancing-stage OA provided only modest protection and failed to reduce IL-18 expression. Moreover, human cartilage plug ex vivo shows ADMSCs modulate the IL-1Î²/IL-18-NLRP3 inflammasome axis. These findings indicate that early ADMSC injection provides superior joint protection, although sustained efficacy may require repeated dosing.",
    "disease": "osteoarthritis",
    "clean_text": "timing of intra articular injection of adipose derived mesenchymal stem cells affects cartilage integrity and il expression in spontaneous osteoarthritis a preclinical study osteoarthritis oa is a progressive joint disease primarily characterized by cartilage degradation a phase i ii clinical trial demonstrated the therapeutic efficacy of a human adipose derived mesenchymal stem cell admsc product in patients with knee oa however it remains unclear whether its efficacy varies with disease stage or whether a single intra articular dose offers sustained protection in this study we used str ort mice a spontaneous oa model to evaluate the effects of a single admsc injection administered during either early or advancing stage oa an additional group received early stage treatment and was analyzed at a later time point to assess durability cartilage integrity chondrocyte phenotypes serum cytokines and subchondral bone structure were examined at three defined time points early admsc injection significantly reduced matrix nonproducing chondrocytes lowered osteoarthritis research society international oarsi scores suppressed aggrecan fragment and matrix metallopeptidase mmp expression and increased sry box transcription factor sox levels in situ rna hybridization showed that admsc xenografts transiently adhered to the cartilage surface and remained detectable post injection micro computed tomography micro ct demonstrated restored trabecular architecture while cytokine profiling revealed reduced interleukin il levels in both serum and cartilage these therapeutic effects persisted for up to six weeks but diminished by ten weeks post injection in contrast admsc treatment during advancing stage oa provided only modest protection and failed to reduce il expression moreover human cartilage plug ex vivo shows admscs modulate the il il nlrp inflammasome axis these findings indicate that early admsc injection provides superior joint protection although sustained efficacy may require repeated dosing"
}